Future perspective of CDH1 mutation in gastric and breast cancers

Bookmark and Share
Published: 22 Jul 2020
Views: 1472
Rating:
Save
Dr. Giovanni Corso - University of Milan, Italy, Meeting president

Dr. Giovanni Corso from the University of Milan, Italy speaks at the Hereditary Breast and Gastric Cancers conference about the future perspective of CDH1 mutation in gastric and breast cancers.

Related Videos

An overview of treatment advances in gastric cancer
Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA
An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )
18 Aug 2022
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and...
Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )
30 Jun 2022
Comment: LUMINA results show that women with low levels of the Ki67 biomarker ca...
Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA
Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )
9 Jun 2022
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal strom...
Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
6 Jun 2022
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )
10 Jun 2021
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...
Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )
8 Jun 2021